التفاصيل البيبلوغرافية
| العنوان: |
Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors. |
| المؤلفون: |
Tamura, Kenji, Hashimoto, Jun, Tanabe, Yuko, Kodaira, Makoto, Yonemori, Kan, Seto, Takashi, Hirai, Fumihiko, Arita, Shuji, Toyokawa, Gouji, Chen, Lan, Yamamoto, Hiroshi, Kawata, Toshio, Lindemann, Justin, Esaki, Taito |
| المصدر: |
Cancer Chemotherapy & Pharmacology; Apr2016, Vol. 77 Issue 4, p787-795, 9p |
| مصطلحات موضوعية: |
PROTEIN kinase B, JAPANESE people, CANCER patients, DRUG dosage, DRUG side effects, PHARMACOKINETICS, DISEASES, CLINICAL trials, COMPARATIVE studies, HETEROCYCLIC compounds, RESEARCH methodology, MEDICAL cooperation, GENETIC mutation, RESEARCH, TRANSFERASES, TUMORS, EVALUATION research |
| مستخلص: |
Purpose: Investigate the safety and tolerability of AZD5363 and define a recommended dose for evaluation in Japanese patients with advanced solid malignancies.Methods: AZD5363 was administered orally as a single dose, and then the dose was escalated to twice daily (bid) in separate continuous (every day) and intermittent (4 days on, 3 days off [4/3] or 2 days on, 5 days off [2/5]) dosing schedules to reach recommended doses defined by dose-limiting toxicity (DLT). Doses for continuous, 4/3, and 2/5 intermittent dosing schedules were 80-400, 360-480, and 640 mg, respectively, and were informed by results from an equivalent study in Caucasian patients.Results: Forty-one patients received AZD5363. DLTs were only experienced with continuous dosing. 97.6 % of patients reported at least one adverse event (AE); most common were diarrhea (78.0 %), hyperglycemia (68.3 %), nausea (56.1 %), and maculopapular rash (56.1 %). Grade ≥3 AEs were reported by 63.4 % of patients. Exposure of AZD5363 was generally dose proportional for both single and multiple doses. Single-dose pharmacokinetics of AZD5363 was generally predictive of multiple-dose pharmacokinetics. Confirmed partial responses were reported by two patients, both of whom were Akt1 (E17K) mutation positive. One patient in the 480 mg bid 4/3 dosing cohort maintained partial response for >2 years.Conclusions: Intermittent dosing of AZD5363 was more tolerable than continuous dosing. 480 mg bid intermittent 4/3 dosing for AZD5363 monotherapy was selected for further investigation. Preliminary evidence of antitumor activity was observed. Akt1 (E17K) is a potent driver mutation that may predict clinical response to AZD5363. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Chemotherapy & Pharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
